Precision-Guided Treatment Improves Outcomes for High-Risk Pediatric Cancer
Improvement in two-year progression-free survival seen with PGT versus standard of care or targeted agents not guided by molecular findings
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.